EvoRadar
Pricing
AI BrainIdeasDice
2238 ideas0 HOT514 WARM1724 COLD
© 2026 Kisum GmbH|ImpressumDatenschutzAGB|GitHub
EvoRadar — AI-Discovered Startup Opportunitiesevoradar.ai
© 2026 Kisum GmbHevoradar.ai · Generated by EvoRadar
← BackWatch AI Discovery

FDA National Priority Voucher Allocation Predictor for Pharma BD Teams

COLD✧ v8pharma business development / regulatoryNorth America16 Mar 2026

One-Liner

A prediction tool for mid-cap pharma BD analysts to estimate the probability of receiving an FDA National Priority Voucher, helping them model NDA submission packaging for faster review.

AI Thinking Process

WHO: BD analyst at mid-cap pharma ($1B-$8B mkt cap) building NPV models for pipeline assets. CURRENT: applies uniform FDA review time assumption to all NDAs, guesses voucher likelihood from press releases.

G102 fires: voucher allocation = bilateral, opaque, no benchmark. Evaluate Pharma, IQVIA, GlobalData have subscription analytics. Not specialised voucher-prediction tools.

Pivot: not predict who will get voucher, but optimise NDA submission to maximise probability of receiving it. NDA Partners / ProEdge do this manually. Software tool form doesn't exist.

G064 fires on pivot: even optimisation is one-shot consulting per drug. Prediction absorbed by Evaluate Pharma/IQVIA. Both shapes consulting-shaped revenue. Kill confirmed.

Kill Reason

Voucher allocation is a one-shot event per drug (G064). Prediction is absorbed by Evaluate Pharma/IQVIA/GlobalData within 12-18 months. The application-optimisation pivot (packaging to maximise voucher probability) is also one-shot consulting per drug — not SaaS-shaped recurring revenue.

Risk Analysis

Risk analysis available for latest engine ideas.

What do you think?

Related ideas you can explore free:

COLDFDA National Priority Voucher Allocation Predictor for Pharma BD Teams

killed: Voucher allocation is a one-shot event per drug (G064). Prediction is absorbed by Evaluate Pharma/IQVIA/GlobalData within 12-18 months. The application-optimisation pivot (packaging to maximise voucher probability) is also one-shot consulting per drug — not SaaS-shaped recurring revenue.

COLDMulti-Chip AI Orchestration Platform

killed: Open-source middleware (HAMi) already provides heterogeneous AI computing virtualization for free. Proprietary play is squeezed between free open-source and vertically integrated hardware vendor ecosystem.

COLDGPU Compute Brokerage

killed: 5+ funded competitors including Cast AI ($1B valuation), OneChronos (backed by Nobel laureate), Akash Network (decentralized, 80% cheaper), Argentum AI (blockchain-settled). Market is claimed with massive capital.